Stammdaten
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
Unternehmen & Branche
| Name | INTENSITY THERAPEUTICS, INC. |
|---|---|
| Ticker | INTS |
| CIK | 0001567264 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 9,9 Mio. USD |
| Beta | 4,23 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -11,606,000 | -8.56 | 14,101,000 | 11,876,000 | |
| 2025-09-30 | 10-Q | -2,671,000 | -0.06 | 9,585,000 | 7,222,000 | |
| 2025-06-30 | 10-Q | -2,537,000 | -0.13 | 4,443,000 | 2,184,000 | |
| 2025-03-31 | 10-Q | -3,347,000 | -0.22 | 3,065,000 | 334,000 | |
| 2024-12-31 | 10-K | -16,268,000 | -29.24 | 4,783,000 | 2,918,000 | |
| 2024-09-30 | 10-Q | -3,513,000 | -0.25 | 5,213,000 | 2,779,000 | |
| 2024-06-30 | 10-Q | -4,971,000 | -0.36 | 8,673,000 | 5,345,000 | |
| 2024-03-31 | 10-Q | -4,603,000 | -0.34 | 12,408,000 | 9,722,000 | |
| 2023-12-31 | 10-K | -10,538,000 | -1.38 | 17,295,000 | 13,162,000 | |
| 2023-09-30 | 10-Q | -2,329,000 | -0.17 | 16,815,789 | 15,911,000 | |
| 2023-06-30 | 10-Q | -3,701,000 | -1.43 | 18,227,963 | 15,133,000 | |
| 2023-03-31 | 10-Q | -1,336,000 | -0.39 | -15,963,000 | ||
| 2022-12-31 | 10-K | -7,582,000 | -2.22 | 1,757,000 | -15,098,000 | |
| 2022-09-30 | 10-Q | -1,774,867 | -0.52 | -14,214,327 | ||
| 2022-06-30 | 10-Q | -1,927,642 | -0.57 | -12,480,171 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.